# US 2021/0275537 A1 · Compounds comprising tricyclic heterocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275537 A1
- Document ID: US20210275537A1
- Status: Published application
- Kind: A1
- Application number: 17/071,543
- Filed: 2020-10-15
- Published: 2021-09-09
- Earliest claimed: 2015-08-19
- Assignees: Karus Therapeutics Limited
- Applicants: Karus Therapeutics Limited
- Inventors: Stephen Joseph Shuttleworth; Elizabeth Ann Bone; Franck Alexandre Silva; Alexander Richard Liam Cecil
- Web page: https://patentgrep.com/patent/US20210275537A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:

## Claims

### Claim 1

A pharmaceutical composition comprising a succinate salt of a compound, wherein the compound is represented by:
and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition according to claim 1, further comprising a surfactant in an amount of from 0.1 to 5 wt % based on the total weight of the composition.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the composition is in the form of a tablet or capsule.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the composition comprises at least two pharmaceutical excipients.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the compound is present in an amount of from 5 to 30 wt % based on the total weight of the composition.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein a filler is present in an amount of from 10 to 90 wt % based on the total weight of the composition.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein a binder is present in an amount of from 0.1 to 20 wt % based on the total weight of the composition.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein a disintegrant is present in an amount of from 1 to 20 wt % based on the total weight of the composition.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein a lubricant is present in an amount of from 0.1 to 10 wt % based on the total weight of the composition.

### Claim 11 (depends on 1)

The composition according to claim 1, wherein the composition comprises:
1 to 50 wt % of a compound according to claims 1;
10 to 90 wt % of at least one filler;
0.1 to 20 wt % of at least one binder;
1 to 20 wt % of at least one disintegrant; and
0.1 to 10 wt % of at least one lubricant or glidant.

### Claim at position 12

-30. (canceled)

### Claim 31 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical excipient is selected from the group consisting of lactose monohydrate, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, magnesium stearate, and sodium lauryl sulfate.

### Claim 32 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises sodium lauryl sulfate, lactose monohydrate, microcrystalline cellulose, crospovidone, hydroxypropyl cellulose, and magnesium stearate.
